DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.92 USD | -2.79% |
|
-2.79% | +110.77% |
| May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
| May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Chart calendar Dianthus Therapeutics, Inc.
edb8dbdc56919fd42be84a2f.F6hXRyW2C9pYRsc68WMcXgPXDh8sfbF0vcp--kTaVHo.Z-5vH2bxX7ExDOpzgCxYaUa8bV5vD-gZ-oAKuTe0JQAv5BQNf_5lqAwMhg~cc62e5840483410916e4dd188542f6ad
Upcoming events on Dianthus Therapeutics, Inc.
Past events on Dianthus Therapeutics, Inc.
| 2024-05-23 09:00 am | Annual General Meeting |
| 2024-05-14 07:20 pm | BofA Securities Health Care Conference |
| 2024-05-09 04:01 pm | Q1 2024 Earnings Release |
| 2024-04-14 | American Academy of Neurology Meeting |
| 2024-03-21 04:01 pm | Q4 2023 Earnings Release |
| 2024-03-04 02:50 pm | TD Cowen Health Care Conference |
| 2024-02-07 10:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-11 01:30 pm | JPMorgan Healthcare Conference |
| 2023-11-27 | Evercore ISI HealthCONx Conference |
| 2023-11-13 | Jefferies London Healthcare Conference |
| 2023-11-09 04:05 pm | Q3 2023 Earnings Release |
| 2023-11-05 | Guggenheim Securities Inflammation & Immunology Conference |
Annual results
| Fiscal Period | December | 2022 | 2023 | 2024 |
|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 2,83 2,52 12.13% | 1,82 |
|
EBITDA | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -48,2 -63,0 23.48% | -77,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -43,6 -58,1 25.1% | -63,7 |
|
Net income Million USD | Released Forecast Spread | -28,5 | -43,6 -58,1 25.07% | -63,7 |
|
EPS USD | Released Forecast Spread | -7,10 | -8,45 -5,62 -50.46% | -2,19 |
| Announcement Date | 01/08/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,92 0,25 269.6% | 0,46 0,44 4.15% | 0,87 0,37 135.33% | 0,31 | 0,31 | 0,31 | 0,32 | 0,32 |
|
EBIT Million USD | Released Forecast Spread | -15,8 -9,20 -71.38% | -13,0 -15,8 18.11% | -17,8 -14,7 -21.58% | -18,6 | -19,9 | -21,3 | -18,9 | -19,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,8 -8,31 -77.71% | -10,6 -15,2 30.38% | -13,7 -13,5 -1.81% | -15,0 | -16,3 | -18,6 | -15,6 | -16,6 |
|
Net income Million USD | Released Forecast Spread | -14,8 -8,31 -77.71% | -10,6 -15,2 30.38% | -13,7 -13,5 -1.81% | -15,0 | -16,3 | -18,6 | -15,6 | -16,6 |
|
EPS USD | Released Forecast Spread | -3,78 -0,56 -575% | -1,02 | -0,54 -0,44 -23.29% | -0,53 | -0,58 | -0,63 | -0,55 | -0,60 |
| Announcement Date | 09/11/23 | 21/03/24 | 09/05/24 | - | - | - | - | - |
More events
Past sector events for Dianthus Therapeutics, Inc.
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- DNTH Stock
- Calendar Dianthus Therapeutics, Inc.
